P4420: Liraglutide, a drug developed to treat type 2 diabetes, has protective effects in mouse models of Alzheimers disease
At a 90-degree angle with a skin pinch, this length reliably reaches the subcutaneous layer without penetrating muscle in most body types
Lilly's NEJM-published phase 2 study showed: 17.5% mean weight reduction at 24 weeks with the highest dose 24.2% mean weight reduction at 48 weeks with the highest dose Dose-dependent improvement in glycemic markers GI side effects that were common but usually manageable That was the moment the molecule stopped looking like a clever concept and started looking like a serious obesity drug candidate
It helps with muscle building
Reinforce the role of the nurse in communicating relevant information to the dietitian and promoting patient understanding
Primary Finding: Weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% compared with placebo (HR 0.80, 95% CI 0.720.90)